company background image
2SX logo

scPharmaceuticals DB:2SX Stock Report

Last Price

€3.16

Market Cap

€158.4m

7D

-4.2%

1Y

-32.2%

Updated

07 Feb, 2025

Data

Company Financials +

scPharmaceuticals Inc.

DB:2SX Stock Report

Market Cap: €158.4m

2SX Stock Overview

A pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. More details

2SX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 97.7% below our estimate of its fair value

Earnings are forecast to grow 58.88% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the German market


My Notes

Capture your thoughts, links and company narrative

scPharmaceuticals Inc. Competitors

MPH Health Care

DB:93M1

€98.5m

PharmaSGP Holding

XTRA:PSG

€335.7m

Apontis Pharma

XTRA:APPH

€92.9m

Cantourage Group

XTRA:HIGH

€59.1m

Price History & Performance

Summary of share price highs, lows and changes for scPharmaceuticals
Historical stock prices
Current Share PriceUS$3.16
52 Week HighUS$5.70
52 Week LowUS$2.98
Beta0.10
1 Month Change-4.24%
3 Month Change-21.00%
1 Year Change-32.19%
3 Year Change-26.17%
5 Year Change-52.84%
Change since IPO-65.76%

Recent News & Updates

Recent updates

Shareholder Returns

2SXDE PharmaceuticalsDE Market
7D-4.2%-3.9%-0.02%
1Y-32.2%-12.4%15.1%

Return vs Industry: 2SX underperformed the German Pharmaceuticals industry which returned -10.6% over the past year.

Return vs Market: 2SX underperformed the German Market which returned 15.3% over the past year.

Price Volatility

Is 2SX's price volatile compared to industry and market?
2SX volatility
2SX Average Weekly Movement9.1%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2SX's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 2SX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2013136John Tuckerwww.scpharmaceuticals.com

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company’s product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector.

scPharmaceuticals Inc. Fundamentals Summary

How do scPharmaceuticals's earnings and revenue compare to its market cap?
2SX fundamental statistics
Market cap€158.43m
Earnings (TTM)-€77.57m
Revenue (TTM)€29.32m

5.4x

P/S Ratio

-2.0x

P/E Ratio

Is 2SX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2SX income statement (TTM)
RevenueUS$30.28m
Cost of RevenueUS$9.17m
Gross ProfitUS$21.11m
Other ExpensesUS$101.22m
Earnings-US$80.11m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.60
Gross Margin69.72%
Net Profit Margin-264.60%
Debt/Equity Ratio166.4%

How did 2SX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 13:31
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

scPharmaceuticals Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
null nullBMO Capital Markets Equity Research
Chase KnickerbockerCraig-Hallum Capital Group LLC